Keryx Biopharmaceuticals Inc., of Boston, reported first quarter revenue of approximately $1.2 million, which included U.S. Auryxia (ferric citrate) product revenue of $422,000 and license revenue of $753,000 associated with royalties received on ferric citrate sales in Japan.